New trials, publications, preprints and grants on this target, month by month.
Trial
Safety and Efficacy of a STOPping Strategy Versus Classical Maintenance Dose of JAK Inhibitors in Deep Remission Patients With Ulcerative Colitis
1 Jan 2027· PHASE4 · NOT_YET_RECRUITING· CTGOV
Trial
The Impact of Rheumatoid Arthritis Treatments on the Modulation of Extracellular Vesicles and Other Biomarkers Involved in the Development of Lung Cancer
1 Dec 2026· NA · NOT_YET_RECRUITING· CTGOV
Trial
Revumenib in Patients With Myelofibrosis
1 Dec 2026· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Corrigendum to: Bone marrow mesenchymal stem cells relieve rheumatoid arthritis by blocking JAK/STAT and TLR-4/NF-?B pathways.
1 Dec 2026· Pakistan journal of pharmaceutical sciences· PUBMED
Trial
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
11 Nov 2026· PHASE1_PHASE2 · RECRUITING· CTGOV
Trial
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
11 Nov 2026· PHASE1 · RECRUITING· CTGOV
Publication
Alteration of macrophage infiltrates in the tumor immune microenvironment following Janus kinase 1 (JAK) inhibition: analysis from a prospective clinical trial in Leiomyosarcoma.
6 Nov 2026· Oncoimmunology· PUBMED
Publication
Impact of nano-chitosan solution on psoriasis-like thin skin lesion induced by imiquimod in Wistar rats: Exploring novel epigenetic role targeting miR-155, JAK2/STAT3/RORC/IL-17A, and MyD88/NF-κB pathways.
4 Nov 2026· Histology and histopathology· PUBMED
Publication
Age-stratified risk of major adverse cardiovascular events with JAK inhibitors in rheumatoid arthritis: A nationwide cohort study.
2 Nov 2026· Journal of autoimmunity· PUBMED
Publication
JAK1/2 inhibition promotes aggressive cutaneous carcinogenesis through COT kinase-mediated alternative MAPK pathway activation.
2 Nov 2026· The Journal of clinical investigation· PUBMED
Trial
Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP Trial
1 Nov 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis
1 Nov 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Peri-Transplant Gecacitinib in Patients With Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
1 Nov 2026· NA · NOT_YET_RECRUITING· CTGOV
Publication
Xiaoshen formula delays progression of diabetic kidney disease and improves glucose and lipid metabolism: Association with the JAK/STAT pathway.
1 Nov 2026· Pakistan journal of pharmaceutical sciences· PUBMED
Publication
Jolkinolide B induces apoptosis and G1 arrest in A549 cells via JAK2/STAT3 inhibition.
1 Nov 2026· Pakistan journal of pharmaceutical sciences· PUBMED
Publication
The Histone Lactylation of KREMEN2 Inhibits Ferroptosis Through the JAK2/STAT3/GPX4 Axis and Promotes the Progression of Mantle Cell Lymphoma.
1 Nov 2026· Hematological oncology· PUBMED
Publication
Progression to Psoriatic Arthritis Among Psoriasis Patients Treated With JAK Inhibitors Compared With IL-17/23 Inhibitors.
1 Nov 2026· Journal of drugs in dermatology : JDD· PUBMED
Publication
Bone marrow mesenchymal stem cells relieve rheumatoid arthritis by blocking JAK/STAT and TLR-4/NF-κB pathways.
1 Nov 2026· Pakistan journal of pharmaceutical sciences· PUBMED
Publication
PELO links PTEN loss to JAK1/STAT1-mediated inflammation and prostate tumor progression by stabilizing JAK1-PIK3R3 interactions.
31 Oct 2026· Cell death and differentiation· PUBMED
Publication
JAK1 Inhibitors for Eczematous Eruptions Following Anti-IL-17A Therapy in Psoriasis: A Case Series.
31 Oct 2026· Psoriasis (Auckland, N.Z.)· PUBMED
Publication
JAK inhibitor retention and adverse event-related discontinuation in elderly patients with rheumatoid arthritis: a real-world cohort study.
31 Oct 2026· Clinical rheumatology· PUBMED
Publication
GPR183 senses 7α,25-OHC to drive Treg differentiation and tumor immune evasion via AXL-JAK2-STAT5 signaling.
30 Oct 2026· Science advances· PUBMED
Publication
A pectic polysaccharide from Lonicera japonica alleviates DNCB-induced atopic dermatitis-like inflammation associated with gut microbial and metabolic alterations and reduced cutaneous JAK2/STAT3 activation and Th17 responses.
29 Oct 2026· Journal of ethnopharmacology· PUBMED
Publication
Collagen type I alpha 1 chain induces M2 macrophage polarization via integrin α2β1/JAK2/STAT3 pathway to promote gastric cancer progression.
28 Oct 2026· Tissue & cell· PUBMED
Publication
3,4-Dimethoxyacetophenone ameliorates epileptogenesis by suppressing BDNF, c-fos, and JAK-2/ STAT-3 expression in a pentylenetetrazole-induced kindling model of epilepsy.
28 Oct 2026· Neuropharmacology· PUBMED
Publication
CXCL9 Knockdown Inhibits Tumor Progression and Angiogenesis in Clear Cell Renal Cell Carcinoma via JAK-STAT3 Signaling Pathway.
28 Oct 2026· Oncology research· PUBMED
Publication
QRISK3 Assessment Identified Essential Thrombocythemia Patients at High Risk of Thrombotic Events Regardless of Revised IPSET-T Score and JAK2 Mutational Status.
28 Oct 2026· EJHaem· PUBMED
Publication
Non-canonical function of SCIMP restricts JAK1 activity to counteract immune evasion in bladder cancer.
27 Oct 2026· Journal for immunotherapy of cancer· PUBMED
Publication
The JAK3/IL-2Rα axis in Helicobacter pylori-associated macrophage reprogramming: A narrative review of a proposed immunoregulatory framework.
27 Oct 2026· The Journal of international medical research· PUBMED
Publication
Refining atopic dermatitis pathogenesis: Early-life trajectories, noncanonical cytokines, and JAK-STAT signaling.
27 Oct 2026· The Journal of allergy and clinical immunology· PUBMED